普拉克索在治疗帕金森病中对心脏瓣膜不良反应的荟萃分析评价

目的:系统评价普拉克索在治疗帕金森病中对患者心脏瓣膜不良反应的情况。方法:通过检索Pubmed、Embase、CochraneDatabase及中国生物医学文献数据库,检索国内外2008年8月前已发表的普拉克索在治疗帕金森病中对心脏瓣膜不良反应的诊断试验,对所纳入的研究进行质量评价及荟萃分析。结果:共纳入5项研究(492例),荟萃分析结果显示:普拉克索组与未服用多巴胺受体激动剂的对照组左房室瓣反流发生率差异无统计学意义[加权均数差值(WMD)=1.33,95%可信区间(CI):0.53～3.36],右房室瓣反流发生率差异无统计学意义(WMD=1.95,95%CI:0.60～6.35),主动脉瓣反流发生率差异无统计学意义(WMD=1.04,95%CI:0.42～2.62)。结论:普拉克索对帕金森病患者心脏瓣膜的不良反应较小,但还需更多高质量研究予以进一步证实。

Systematic review on adverse effect of pramipexole on the heart valves in patients with Parkiason's disease

Objective To systemically review the prevalence of adverse effects of pramipexole on the heart valves in patients with Parkinson＇s disease. Methods Pubmed, Embase, Coehrane Library and Chinese biomedical literature database were searched to identify studies published before August, 2008 on the prevalence of the heart valve adverse effect of pramipexole on the heart valves in patients with Parkinson＇s disease. Results Five studies involving 492 patients were enrolled. The results of recta-analysis showed that： （1）there was no significant difference of prevalence of mitral regurgitation between pramipexole group and control group （WMD=1.33, 95%CI： 0.53-3.36; （2）there was no significant difference of prevalence of tricuspid regurgitation between pramipexole group and control group （WMD=1.95, 95%CI： 0.60-6.35）; （3）there was no significant difference of prevalence of aortic regurgitation between pramipexole group and control group （WMD=1.04, 95%CI： 0.42-2.62）. Conclusions The pramipexole has only a low risk in inducing adverse effect on the cardiac valves in treating patients with Parkinson＇s disease. However, further advanced studies are needed to confirm this conclusion.